These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 17504105

  • 1. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA.
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [Abstract] [Full Text] [Related]

  • 2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA.
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [Abstract] [Full Text] [Related]

  • 3. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA.
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [Abstract] [Full Text] [Related]

  • 4. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
    Lipton SA, Gu Z, Nakamura T.
    Int Rev Neurobiol; 2007 Apr; 82():1-27. PubMed ID: 17678953
    [Abstract] [Full Text] [Related]

  • 5. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA.
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [Abstract] [Full Text] [Related]

  • 6. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS, Lipton SA.
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [Abstract] [Full Text] [Related]

  • 7. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK, Kaul CL, Ramarao P.
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [Abstract] [Full Text] [Related]

  • 8. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X.
    Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
    [Abstract] [Full Text] [Related]

  • 9. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
    Lipton SA.
    Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
    [Abstract] [Full Text] [Related]

  • 10. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
    Koch HJ, Szecsey A, Haen E.
    Curr Pharm Des; 2004 Feb; 10(3):253-9. PubMed ID: 14754385
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage.
    Lipton SA.
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S38-46. PubMed ID: 12852433
    [Abstract] [Full Text] [Related]

  • 13. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A, Alfaro V.
    Rev Neurol; 2003 Apr; 42(10):607-16. PubMed ID: 16703529
    [Abstract] [Full Text] [Related]

  • 14. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL, Lladó A, Rami L.
    Am J Alzheimers Dis Other Demen; 2005 Apr; 20(2):77-85. PubMed ID: 15844753
    [Abstract] [Full Text] [Related]

  • 15. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
    Seki M, Lipton SA.
    Prog Brain Res; 2008 Apr; 173():495-510. PubMed ID: 18929130
    [Abstract] [Full Text] [Related]

  • 16. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
    Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA.
    J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R, Adityanjee, Dysken M.
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.